Plasma endothelin-1 (ET-1) is elevated in patients with sickle cell disease (SCD). Hydroxyurea (HU) is the only drug with demonstrated clinical efficacy in SCD. Here we show that treatment with HU results in a decreased concentration of circulating ET-1 which is not correlated with the HU-induced increase in HbF level. Blunting of the ET-1 vasoconstrictive stimulus could contribute to the beneficial effects of HU.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
plasma endothelin-1
8
sickle cell
8
cell disease
8
decreased plasma
4
endothelin-1 levels
4
levels children
4
children sickle
4
disease treated
4
treated hydroxyurea
4
hydroxyurea plasma
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!